Frontiers in Immunology (Nov 2022)

A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains

  • Sandra Nakandakari-Higa,
  • Roham Parsa,
  • Bernardo S. Reis,
  • Renan V. H. de Carvalho,
  • Luka Mesin,
  • Hans-Heinrich Hoffmann,
  • Juliana Bortolatto,
  • Juliana Bortolatto,
  • Hiromi Muramatsu,
  • Paulo. J. C. Lin,
  • Angelina M. Bilate,
  • Charles M. Rice,
  • Norbert Pardi,
  • Daniel Mucida,
  • Daniel Mucida,
  • Gabriel D. Victora,
  • Maria Cecilia C. Canesso,
  • Maria Cecilia C. Canesso

DOI
https://doi.org/10.3389/fimmu.2022.1007080
Journal volume & issue
Vol. 13

Abstract

Read online

Efficient mouse models to study SARS-CoV-2 infection are critical for the development and assessment of vaccines and therapeutic approaches to mitigate the current pandemic and prevent reemergence of COVID-19. While the first generation of mouse models allowed SARS-CoV-2 infection and pathogenesis, they relied on ectopic expression and non-physiological levels of human angiotensin-converting enzyme 2 (hACE2). Here we generated a mouse model carrying the minimal set of modifications necessary for productive infection with multiple strains of SARS-CoV-2. Substitution of only three amino acids in the otherwise native mouse Ace2 locus (Ace2TripleMutant or Ace2™), was sufficient to render mice susceptible to both SARS-CoV-2 strains USA-WA1/2020 and B.1.1.529 (Omicron). Infected Ace2™ mice exhibited weight loss and lung damage and inflammation, similar to COVID-19 patients. Previous exposure to USA-WA1/2020 or mRNA vaccination generated memory B cells that participated in plasmablast responses during breakthrough B.1.1.529 infection. Thus, the Ace2™ mouse replicates human disease after SARS-CoV-2 infection and provides a tool to study immune responses to sequential infections in mice.

Keywords